Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459465 | 1.00 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4759736 | 1.00 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4759732 | 1.00 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5459468 | 1.00 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6826523 | 0.86 | SLC6A3 (0.54) | SLC6A3 | |
| SCHEMBL3436817 | 0.85 | MEN1 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3832793 | 0.84 | SLC6A3 (0.72) | SLC6A3 | |
| SCHEMBL3833873 | 0.84 | SLC6A3 (0.72) | SLC6A3 | |
| SCHEMBL1944023 | 0.84 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL7812342 | 0.84 | SLC6A3 (0.72) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015071831-A1 | AN IMPROVED PROCESS FOR MINIMISING THE FORMATION OF DEHALOGENATED BYPRODUCTS | Piramal Enterprises Limited (IN) | 2015-05-21 | — | — | WO | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| EP-1966137-A2 | PIPERIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| WO-2007072150-A2 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | PFIZER INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | PFIZER INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007034270-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (-) TRANS-N-METHYL PAROXETINE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-03-29 | — | — | WO | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| WO-2004043921-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES. | NATCO PHARMA LIMITED (IN) | 2004-05-27 | — | — | WO | disclosed |
| CN-1068597-C | Process for preparing 4 -aryl -piperidine derivatives | NOVO NORDISK AS (DK) | 2001-07-18 | — | — | CN | disclosed |
| EP-1074550-A1 | Process for the preparation of 3-substituted 4-phenyl-piperidine derivatives | CHEMI S.p.A. (IT) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000020390-A1 | MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2000-04-13 | — | — | WO | disclosed |
| CN-1184476-A | Process for preparing 4 -aryl -piperidine derivatives | NOVO NORDISK AS (DK) | 1998-06-10 | — | — | CN | disclosed |
| EP-0828735-A1 | PROCESS FOR PREPARING 4-ARYL-PIPERIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996036636-A1 | PROCESS FOR PREPARING 4-ARYL-PIPERIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1996-11-21 | — | — | WO | disclosed |
| EP-0284395-B1 | NOVEL GLYCEROL DERIVATIVE AND ANTI-HYPERTENSIVE AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| US-5183811-A | Glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-02-02 | — | — | US | disclosed |
| US-4962096-A | WITH REDUCED PLATELET AGGREGATING ACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0284395-A2 | Novel glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | CFTR, HDAC10, RPP30 | SLC6A3 2127/4885SLC6A2 2730/4885SLC6A4 1044/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | SLC6A3 58/4885SLC6A2 150/4885SLC6A4 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.